NASDAQ$TERN
Terns Pharmaceuticals Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Terns Pharmaceuticals reported financial results for Q4 2023 and provided corporate updates.
Terns Pharmaceuticals reported a net loss of $21.0 million for the fourth quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $263.4 million as of December 31, 2023, which is expected to fund operations into 2026. The company is advancing its clinical programs for TERN-601 and TERN-701.
- Global Phase 1 CARDINAL trial for TERN-701 initiated in Q4 2023 and is progressing.
- Phase 1 clinical trial of Terns’ lead oral GLP-1 receptor agonist TERN-601 is ongoing.
- FDA granted Orphan Drug Designation for TERN-701 for the treatment of chronic myeloid leukemia in March 2024.
- Amy Burroughs appointed as chief executive officer and board member in February 2024.
Headline financials
Revenue & EPS history
Terns · Revenue · Quarterly
$1.32M
Forward guidance
Terns expects its cash, cash equivalents and marketable securities to be sufficient to support its planned operating expenses into 2026.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2023
-0.3%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+16.4%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+19.8%
Q4 2022
Best reaction
-23.0%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.3% | -0.0% | — | |
| Q3 2025 | +7.6% | +18.0% | +146.3% | |
| Q2 2025 | -6.8% | +3.6% | +18.7% | |
| Q1 2025 | -0.7% | -4.1% | +22.3% | |
| Q4 2024 | -2.7% | -1.3% | -23.6% | |
| Q3 2024 | -9.1% | -17.3% | -11.7% | |
| Q2 2024 | -4.6% | -11.8% | -1.7% | |
| Q1 2024 | +7.7% | +6.1% | +32.9% | |
| Q4 2023 | +1.7% | -15.0% | -27.4% | |
| Q3 2023 | +14.2% | +10.1% | +92.3% | |
| Q2 2023 | -9.5% | +0.8% | -21.5% | |
| Q1 2023 | -15.2% | -20.3% | -7.0% | |
| Q4 2022 | +19.8% | +32.7% | +42.3% | |
| Q3 2022 | -23.0% | -26.7% | -12.2% | |
| Q2 2022 | -5.5% | +39.2% | +75.1% | |
| Q1 2022 | +4.0% | -0.7% | +26.5% | |
| Q4 2021 | +4.1% | +3.5% | -5.4% | |
| Q3 2021 | -1.2% | -5.9% | -30.9% | |
| Q2 2021 | +4.3% | +3.5% | -0.9% | |
| Q1 2021 | +3.6% | +5.6% | +13.5% | |
| Q4 2020 | +5.8% | -0.9% | +1.2% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro